Two Sigma Advisers’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Two Sigma Advisers’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,600	Closed	-$342K	–	2800
2020 Q4	$342K	Buy	+2,600	New	+$230K	﹤0.01%	2005
2020 Q1	–	Sell	-4,900	Closed	-$281K	–	2623
2019 Q4	$281K	Buy	+4,900	New	+$243K	﹤0.01%	2084

Two Sigma Advisers's EIDX Position: Q1 2021 in Review

Two Sigma Advisers sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 2,600 shares — an estimated $342K sold.

Two Sigma Advisers first reported a position in EIDX in Q4 2019 and held it in 2 quarters. The position peaked at $342K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Two Sigma Advisers reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Two Sigma Advisers sold 2,600 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $342K.
Two Sigma Advisers first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Two Sigma Advisers's Eidos Therapeutics, Inc. Common Stock position peaked at $342K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Two Sigma Advisers's 13F filing for Q1 2021, filed 17 May 2021.